PT-141 (Bremelanotide) Research Peptide

PT-141 is a synthetic research peptide developed from structural modifications of the melanocortin analog Melanotan II. In experimental models, PT-141 has been studied for its selective interaction with melanocortin receptors, particularly MC3R and MC4R, which are involved in central neuropeptide signaling pathways. Preclinical research commonly utilizes PT-141 to examine G-protein–coupled receptor (GPCR) activation, hypothalamic signaling mechanisms, and downstream neuroendocrine modulation. Its receptor selectivity and defined mechanism of action make PT-141 a useful tool for investigating melanocortin system biology and neuronal signaling dynamics in controlled laboratory environments.

Evidence classification: Bremelanotide has controlled clinical research in an FDA-approved pharmaceutical formulation for a specific indication; that evidence does not apply to research-grade material.